Arcutis Biotherapeutics, Inc. beat EPS estimates 67% of the time across 18 reported quarters (12 beats, 6 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $0.07 | — | — | Miss |
| Q12026 FY2026 | $-0.02 | $-0.09 | -350.0% | Miss |
| 2026-02-25 | $0.03 | — | — | Miss |
| Q3 FY2025 | $-0.10 | $0.06 | +160.0% | Beat |
| Q3 FY2025 | $-0.18 | $-0.13 | +27.8% | Beat |
| Q3 FY2025 | $-0.21 | $-0.20 | +4.8% | Beat |
| 2025-02-25 | $-0.28 | $-0.09 | +67.9% | Beat |
| Q3 FY2024 | $-0.42 | $-0.33 | +21.4% | Beat |
| Q3 FY2024 | $-0.48 | $-0.42 | +12.5% | Beat |
| Q3 FY2024 | $-0.60 | $-0.32 | +46.7% | Beat |
| 2024-02-27 | $-0.65 | $-0.72 | -10.8% | Miss |
| Q3 FY2023 | $-0.90 | $-0.73 | +18.9% | Beat |
Back to ARQT overview · ARQT holders · ARQT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.